Back to GetFilings.com



Table of Contents



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549


FORM 10-Q


(Mark One)

     
x
  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 26, 2004

OR

     
o
  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

For the transition period from ________to _________

Commission file number 000-26911

THERMA-WAVE, INC.


(Exact Name of Registrant as Specified in Its Charter)
     
Delaware   94-3000561

 
 
 
(State or Other Jurisdiction of Incorporation or Organization)   (I.R.S. Employer Identification Number)

1250 Reliance Way
Fremont, California 94539


(Address of Principal Executive Offices Including Zip Code)

(510) 668-2200


(Registrant’s Telephone Number, Including Area Code)

     Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES x NO o

     Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act). YES x NO o

     Indicate the number of shares outstanding of the issuer’s class of common stock, as of the latest practical date:

     
Class
Common stock, $0.01 par value
  Outstanding as of October 26, 2004
36,002,246



 


Table of Contents

THERMA-WAVE, INC.
TABLE OF CONTENTS

         
    Page No.
       
       
    3  
    4  
    6  
    7  
    15  
    22  
    23  
       
    24  
    24  
    24  
    24  
    24  
    24  
       
 EXHIBIT 22.1
 EXHIBIT 31.1
 EXHIBIT 31.2
 EXHIBIT 32.1
 EXHIBIT 32.2

2


Table of Contents

PART I — FINANCIAL INFORMATION

Item 1. Financial Statements

THERMA-WAVE, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share data)
(Unaudited)
                 
    September 30,   March 31,
    2004
  2004
ASSETS
               
Current assets:
               
Cash and cash equivalents
  $ 17,205     $ 23,899  
Accounts receivable, net of allowances of $724 and $907 as of September 30, 2004 and March 31, 2004, respectively
    18,383       14,772  
Inventories
    22,603       17,169  
Other current assets
    2,489       2,075  
 
   
 
     
 
 
Total current assets
    60,680       57,915  
Property and equipment, net
    3,831       4,564  
Other assets, net
    2,642       2,710  
 
   
 
     
 
 
Total assets
  $ 67,153     $ 65,189  
 
   
 
     
 
 
LIABILITIES AND STOCKHOLDERS’ EQUITY
               
Current liabilities:
               
Accounts payable
  $ 10,074     $ 7,420  
Accrued liabilities
    15,400       15,730  
Deferred revenues
    6,098       6,887  
 
   
 
     
 
 
Total current liabilities
    31,572       30,037  
Non-current deferred revenues
    1,252       1,815  
Other long-term liabilities
    1,090       1,073  
 
   
 
     
 
 
Total liabilities
    33,914       32,925  
 
   
 
     
 
 
Commitments and contingencies (Note 5)
               
Stockholders’ equity:
               
Common stock, $0.01 par value; 75,000,000 shares authorized;
               
35,866,187 shares issued and outstanding at September 30, 2004;
               
35,498,025 shares issued and outstanding at March 31, 2004
    359       355  
Additional paid-in capital
    335,176       335,012  
Notes receivable from stockholders
    (174 )     (174 )
Accumulated other comprehensive loss
    (868 )     (735 )
Deferred stock-based compensation
    (380 )     (1,172 )
Accumulated deficit
    (300,874 )     (301,022 )
 
   
 
     
 
 
Total stockholders’ equity
    33,239       32,264  
 
   
 
     
 
 
Total liabilities and stockholders’ equity
  $ 67,153     $ 65,189  
 
   
 
     
 
 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

3


Table of Contents

THERMA-WAVE, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share data)
(Unaudited)
                                 
    Three months ended September 30,
  Six months ended September 30,
    2004
  2003
  2004
  2003
Net revenues
                               
Product
  $ 17,528     $ 9,604     $ 33,717     $ 16,411  
Services and parts
    5,074       4,462       10,036       9,558  
 
   
 
     
 
     
 
     
 
 
Total net revenues
    22,602       14,066       43,753       25,969  
Cost of revenues (1)
    11,830       8,499       22,261       17,570  
 
   
 
     
 
     
 
     
 
 
Gross profit
    10,772       5,567       21,492       8,399  
Operating expenses:
                               
Research and development (2)
    4,412       5,183       8,791       10,131  
Selling, general and administrative (3)
    5,935       5,854       11,691       11,383  
Restructuring, severance and other
          108       373       1,592  
Stock-based compensation expense (benefit) (4)
    (868 )     204       565       414  
 
   
 
     
 
     
 
     
 
 
Total operating expenses
    9,479       11,349       21,420       23,520  
 
   
 
     
 
     
 
     
 
 
Operating income (loss)
    1,293       (5,782 )     72       (15,121 )
 
   
 
     
 
     
 
     
 
 
Other income (expense):
                               
Interest expense
    (8 )     (24 )     (8 )     (45 )
Interest income
    48       66       90       103  
Other, net
    (13 )     12       (3 )     (199 )
 
   
 
     
 
     
 
     
 
 
Total other income (expense), net
    27       54       79       (141 )
 
   
 
     
 
     
 
     
 
 
Income (loss) before provision for income taxes
    1,320       (5,728 )     151       (15,262 )
Provision for income taxes
    3             3        
 
   
 
     
 
     
 
     
 
 
Net income (loss)
  $ 1,317     $ (5,728 )   $ 148     $ (15,262 )
 
   
 
     
 
     
 
     
 
 
Net income (loss) per share:
                               
Basic
  $ 0.04     $ (0.19 )   $ 0.00     $ (0.52 )
Diluted
  $ 0.03     $ (0.19 )   $ 0.00     $ (0.52 )
Weighted average common shares outstanding:
                               
Basic
    35,824       30,036       35,731       29,370  
Diluted
    37,949       30,036       37,882       29,370  


(1)   Includes stock-based compensation expense (benefit) of $(262) and $15 for the three months ended September 30, 2004 and 2003, respectively, and $56 and $16 for the six months ended September 30, 2004 and 2003, respectively.
 
(2)   Stock-based compensation expense (benefit) is reported separately in operating expenses. The amount attributable to research and development is $(564) and $126 for the three months ended September 30, 2004 and 2003, respectively, and $322 and $250 for the six months ended September 30, 2004 and 2003, respectively.

4


Table of Contents

(3)   Stock-based compensation expense (benefit) is reported separately in operating expenses. The amount attributable to selling, general and administrative is $(304) and $78 for the three months ended September 30, 2004 and 2003, respectively, and $243 and $164 for the six months ended September 30, 2004 and 2003, respectively.
 
(4)   Stock-based compensation expense (benefit) related to operating expenses, including research and development (see footnote (2)) and selling, general and administrative (see footnote (3)).

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

5


Table of Contents

THERMA-WAVE, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
(Unaudited)
                 
    Six months ended September 30,
    2004
  2003
Operating activities:
               
Net income (loss)
  $ 148     $ (15,262 )
Adjustments to reconcile net income (loss) to net cash used in operating activities:
               
Depreciation and amortization of property and equipment
    1,322       2,388  
Amortization of intangible assets
    403       598  
Amortization of stock-based compensation
    621       430  
Provision (credit) for doubtful accounts receivable
    (183 )     (1,013 )
Provision for excess, obsolete and reduced-cost inventories
    1,888       3,419  
Loss on disposal of property and equipment
    15       191  
Loss on sale of an investment
          125  
Changes in operating assets and liabilities:
               
Accounts receivable
    (3,428 )     4,169  
Inventories
    (7,322 )     25  
Other assets
    (388 )     1,293  
Accounts payable
    2,654       929  
Accrued and other liabilities
    (313 )     (2,175 )
Deferred revenues
    (1,352 )     345  
 
   
 
     
 
 
Net cash used in operating activities
    (5,935 )     (4,538 )
 
   
 
     
 
 
Investing activities:
               
Purchases of property and equipment
    (604 )     (37 )
Proceeds from sale of an investment
          375  
Purchase of patents
    (361 )     (363 )
 
   
 
     
 
 
Net cash used in investing activities
    (965 )     (25 )
 
   
 
     
 
 
Financing activities:
               
Restricted cash
          1,064  
Proceeds from issuance of common stock
    339       11,988  
Proceeds from note receivable from stockholders
          22  
 
   
 
     
 
 
Net cash provided by financing activities
    339       13,074  
Effect of exchange rates on cash
    (133 )     346  
 
   
 
     
 
 
Net increase (decrease) in cash and cash equivalents
    (6,694 )     8,857  
Cash and cash equivalents at beginning of period
    23,899       13,695  
 
   
 
     
 
 
Cash and cash equivalents at end of period
  $ 17,205     $ 22,552  
 
   
 
     
 
 
Supplementary disclosures:
               
Cash paid for interest
  $     $ 22  
Cash paid for taxes
  $ 239     $ 9  

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

6


Table of Contents

THERMA-WAVE, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(As of September 30, 2004)

1. Basis of Presentation

     The accompanying unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission and include the accounts of Therma-Wave, Inc. (we, our, the “Company”) and its wholly-owned subsidiaries. Certain information and footnote disclosures, normally included in financial statements prepared in accordance with generally accepted accounting principles, have been condensed or omitted pursuant to such rules and regulations. In our opinion, the financial statements reflect all adjustments, consisting only of normal, recurring adjustments, necessary for a fair statement of the financial position at September 30, 2004, the operating results for the three and six months ended September 30, 2004 and 2003, and the cash flows for the six months ended September 30, 2004 and 2003. These financial statements and notes should be read in conjunction with our audited financial statements and the notes thereto included in our Form 10-K for the year ended March 31, 2004.

     The results of operations for the interim periods are not necessarily indicative of the results of operations that may be expected for any other period or for the fiscal year, which ends on April 3, 2005.

     The second quarters of fiscal years 2005 and 2004 and the fiscal year 2004 ended on September 26, 2004, September 28, 2003 and March 28, 2004, respectively. For presentation purposes, the accompanying unaudited condensed consolidated financial statements have been shown as ending on the last day of the calendar quarter closest to each of these dates.

     Revenue Recognition

     Revenues are recognized when our contractual obligations have been performed, title and risk of ownership have passed to the customer, collectibility of the sales price has been reasonably assured and customer acceptance has been obtained, if applicable. Shipments typically are made in compliance with shipment requirements specified in our customer’s purchase order. Freight terms of sales are FOB shipping point unless otherwise negotiated and agreed in writing between our customer and us.

     Systems Revenues. Systems (product) sales are accounted for as multiple-element arrangement sales that require the deferral of a significant portion of revenues in the amount of the greater of the fair market value of installation and related post shipment services or a percentage of payment subject to acceptance. Systems revenues are allocated on a fair value basis to each component of the multiple-element arrangement. Revenues on each element are recognized when the contractual obligations have been performed, title and risk of ownership have passed to the customer, collectibility of the sales price has been reasonably assured and customer acceptance has been obtained, if applicable. Estimated contractual warranty obligations are recorded as cost of revenues when related systems sales are shipped.

     Systems revenues on newly introduced products are deferred at shipment and recognized upon customer acceptance. Systems revenues are also deferred when the customer has the right to return the product for credit. In such cases, systems revenues are not recognized until all of the following conditions have been evidenced after the customer’s purchase order has been fulfilled: the right of return has expired, and any potential returns would require authorization by our company under warranty provisions; the price of sales is fixed or determinable; the payment terms are fixed and enforceable, and collectibility is reasonably assured.

     Services Revenues. We derive services revenues from three primary sources: sale of spare parts, service contracts and service labor. Revenues on the sale of spare parts are recognized when spare parts have been shipped and title and risk of ownership have transferred to the customer and collectibility of the sales price has been reasonably assured. Revenues on service contracts are deferred and recognized on a straight-line basis over the period of the contract. Revenues on time and material services performed are recognized when the services are completed, collectibility of the sales price has been reasonably assured and customer acceptance has been obtained, if applicable.

7


Table of Contents

     Deferred Revenues. Deferred revenues arise from systems (product) sales and service contracts. Revenues on service contracts are deferred and recognized on a straight-line basis over the respective contract term. Systems sales are accounted for as multiple-element arrangements that require the deferral of a significant portion of revenues in the amount of the greater of the fair market value of installation and related post shipment services or the percentage of payment subject to acceptance. Systems revenues are allocated on a fair value basis to each component of the multiple-element arrangement. Revenues on each element are recognized when contractual obligations have been performed, title and risk of ownership have passed to the customer, collectibility of the sales price has been reasonably assured and customer acceptance has been obtained if applicable.

     In accordance with SAB 104, we evaluate our systems sales to determine the appropriate timing for revenue recognition for each of the multiple elements involved in each sale. This sometimes results in deferrals of revenues from the period in which the tool is shipped to future periods.

     Reclassifications

     Certain prior year amounts in the unaudited condensed consolidated statements of cash flows have been changed to conform to current period classifications.

     Stock-Based Compensation

     In October 1995, the Financial Accounting Standards Board issued SFAS No. 123, “Accounting for Stock-Based Compensation.” The Company has applied Accounting Principles Board Opinion No. 25 in accounting for its stock option plans and has adopted the disclosure provisions of SFAS No. 123. In April 2000, the Financial Accounting Standards Board issued FASB Interpretation No. 44, “Accounting for Certain Transactions Involving Stock Compensation: An Interpretation of APB No. 25.” The Company has adopted the provisions of FIN 44, and such adoption did not materially impact the Company’s results of operations. In December 2002, the FASB issued SFAS No. 148, “Accounting for Stock-Based Compensation Transition and Disclosure.” The statement amends SFAS No. 123 to provide alternative methods of transition for a voluntary change to the fair value based method of accounting for stock-based employee compensation. The Company has adopted the disclosure provisions of SFAS No. 148.

     Had compensation costs been determined based upon the fair value at the grant date for awards under the stock option plans and employee stock purchase plans, consistent with the methodology prescribed under SFAS No. 123, our pro forma net loss and pro forma net loss per share under SFAS No. 123 would have been:

                                 
    Three Months Ended   Six Months Ended
    September 30,
  September 30,
    2004
  2003
  2004
  2003
Net income (loss) (in thousands, except per share data)
                               
As reported
  $ 1,317     $ (5,728 )   $ 148     $ (15,262 )
Stock-based employee compensation expense (benefit) included in the determination of net loss, as reported
    (1,130 )     219       621       430  
Stock-based employee compensation expense as determined using the fair value method
    (950 )     (952 )     (2,351 )     (2,148 )
 
   
 
     
 
     
 
     
 
 
Pro forma net loss
  $ (763 )   $ (6,461 )   $ (1,582 )   $ (16,980 )
 
   
 
     
 
     
 
     
 
 
Basic income (loss) per share
                               
As reported
  $ 0.04     $ (0.19 )   $ 0.00     $ (0.52 )
Pro forma
  $ (0.02 )   $ (0.22 )   $ (0.04 )   $ (0.58 )
Diluted income (loss) per share
                               
As reported
  $ 0.03     $ (0.19 )   $ 0.00     $ (0.52 )
Pro forma
  $ (0.02 )   $ (0.22 )   $ (0.04 )   $ (0.58 )

8


Table of Contents

     The weighted average grant-date fair value of our stock options was $2.70 and $1.59 for the three months ended September 30, 2004 and 2003, respectively, and $2.77 and $1.12 for the six months ended September 30, 2004 and 2003, respectively. These values were estimated using the Black-Scholes pricing model with the following assumptions:

                                 
    Three Months Ended   Six Months Ended
    September 30,
  September 30,
    2004
  2003
  2004
  2003
Risk-free interest rate
    3.1 %     4.2 %     3.1 %     3.9 %
Expected dividend yield
                       
Expected volatility
    96 %     118 %     97 %     118 %
Expected life in years
    5.0       2.8       5.0       3.4  

     The weighted average grant-date fair value of our stock purchase rights granted under our employee stock purchase plans was $0.82 and $0.26 for the three months ended September 30, 2004 and 2003, respectively, and $0.27 and $0.24 for the six months ended September 30, 2004 and 2003, respectively. These values were estimated using the Black-Scholes pricing model with the following assumptions:

                                 
    Three Months Ended   Six Months Ended
    September 30,
  September 30,
    2004
  2003
  2004
  2003
Risk-free interest rate
    1.4 %     1.1 %     1.3 %     1.0 %
Expected dividend yield
                       
Expected volatility
    58 %     93 %     77 %     103 %
Expected life in years
    1.24       0.97       1.15       0.85  

     Stock-based employee compensation expense (benefit) included in net income as reported includes amounts for two events, specifically, the stock options assumed during the acquisition of Sensys Corporation, and the stock option exchange on September 10, 2003.

     As part of the acquisition of Sensys, we recorded $3.5 million of stock-based compensation to be amortized over the vesting period of the options. The related deferred stock compensation amortization expenses were $44,000, $0.3 million, and $0.2 million for the three months ended September 30, 2004, June 30, 2004 and September 30, 2003, respectively, a portion of which was included in cost of revenues. For the six months ended September 30, 2004 and 2003, respectively, deferred stock compensation amortization expenses were $0.3 million and $0.4 million. These charges reflect the vesting schedules of the stock options and reductions in headcount due to employee turnover and reduction in force programs that began during fiscal 2003 and continued through the first three quarters of fiscal 2004. As of September 30, 2004, $0.2 million of deferred stock compensation related to the Sensys acquisition remains to be amortized over future periods ending in January 2006.

     We recorded a benefit from the amortization of deferred compensation expense related to the variable accounting treatment for stock options of $1.2 million for the three months ended September 30, 2004. For the six months ended September 30, 2004, we have recorded an expense of $0.3 million from the amortization of deferred compensation expense related to the variable accounting treatment for stock options. These expenses and benefits reflect the options eligible for exchange that were outstanding since September 10, 2003 and the options issued to eligible participants within the six months prior to or following September 10, 2003. Due to variable accounting, compensation expense is being recorded for the pro-rata vesting of these options over time based on increases or decreases in the period-end stock price over and above the exercise price of the new options. In future quarters, the expense could increase as more shares become vested and if the stock price increases. Reductions to expense may also be recorded if the stock price decreases, but such reductions will be limited to the amount of net expense previously recorded.

9


Table of Contents

2. Balance Sheet Components

                 
    September 30,   March 31,
    2004
  2004
    (In thousands)
Inventory:
               
Purchased materials
  $ 8,494     $ 6,066  
Systems in process
    9,911       8,158  
Finished systems
    4,198       2,945  
 
   
 
     
 
 
Total inventory
  $ 22,603     $ 17,169  
 
   
 
     
 
 
                 
    September 30,   March 31,
    2004
  2004
    (In thousands)
Property and equipment:
               
Laboratory and test equipment
  $ 4,846     $ 6,014  
Office furniture and equipment
    10,546       10,100  
Machinery and equipment
    694       819  
Leasehold improvements
    8,639       8,612  
 
   
 
     
 
 
Total property and equipment, gross
    24,725       25,545  
Accumulated depreciation and amortization
    (20,894 )     (20,981 )
 
   
 
     
 
 
Total property and equipment, net
  $ 3,831     $ 4,564  
 
   
 
     
 
 

     During the first six months of fiscal 2005, the company disposed of equipment having a gross value of $1,424,000 and accumulated depreciation of $1,409,000. There was a loss of approximately $15,000 on the disposals.

                 
    September 30,   March 31,
    2004
  2004
    (In thousands)
Accrued liabilities:
               
Accrued compensation and related expenses
  $ 2,663     $ 2,368  
Accrued warranty costs
    1,579       1,731  
Commissions payable
    1,940       893  
Income tax payable
    4,849       4,870  
Other accrued liabilities
    4,369       5,868  
 
   
 
     
 
 
Total accrued liabilities
  $ 15,400     $ 15,730  
 
   
 
     
 
 

3. Comprehensive Income (Loss)

     Comprehensive income (loss) consists of net income (loss) for the period and the change in accumulated foreign currency translation adjustments during the period. For the three months ended September 30, 2004 and 2003, comprehensive income (loss) amounted to approximately $1.3 million and $(5.5) million, respectively. For the six months ended September 30, 2004 and 2003, comprehensive income (loss) amounted to approximately $15,000 and $(14.9) million, respectively.

4. Net Income (Loss) Per Share

     Basic net income (loss) per share is based on the weighted-average number of common shares outstanding excluding contingently issuable or returnable shares such as unvested common stock or shares that contingently convert into common stock upon certain events. Diluted net income (loss) per share is based on the weighted average number of common shares outstanding and the potential dilution of securities, by including stock options, outstanding warrants, less the share equivalents in deferred stock-based compensation related to the Sensys acquisition and the variable accounting treatment of certain stock options in the weighted average number of common shares outstanding for a period, to the extent they are dilutive.

10


Table of Contents

                                 
    Three months ended   Six months ended
    September 30,
  September 30,
    2004
  2003
  2004
  2003
Reconciliation of basic and diluted shares (in thousands except per share data) and net income (loss) per share, basic and diluted:
                               
Weighted average shares for basic net income (loss) per share
    35,824       30,036       35,731       29,370  
Weighted average dilutive stock options outstanding under the treasury stock method
    2,225             2,252        
Deduction for shares repurchasable under the treasury stock method based on the remaining balance in deferred stock compensation related to outstanding stock options from the Sensys acquisition and the variable accounting treatment of certain stock options
    (100 )           (101 )      
 
   
 
     
 
     
 
     
 
 
Weighted average shares for diluted net income (loss) per share
    37,949       30,036       37,882       29,370  
 
   
 
     
 
     
 
     
 
 
Net income (loss)
  $ 1,317     $ (5,728 )   $ 148     $ (15,262 )
Net income per share – basic
  $ 0.04     $ (0.19 )   $ 0.00     $ (0.52 )
Net income per share – diluted
  $ 0.03     $ (0.19 )   $ 0.00     $ (0.52 )

     The following table summarizes securities outstanding (in thousands) as of September 30, 2004 and 2003, respectively, which were not included in the calculation of diluted net income (loss) per share for the three months and six months ending September 30, 2004 and 2003, respectively.

                 
    As of September 30,
    2004
  2003
Stock options
    2,661       5,209  
Warrants
    47       79  

     The stock options outstanding that were excluded from the net income (loss) per share had a weighted average exercise price at September 30, 2004 and 2003 of $6.63 and $9.07, respectively. The warrants outstanding that were excluded from the net income (loss) per share had a weighted average exercise price at September 30, 2004 and 2003 of $3.82 and $3.68, respectively.

5. Commitments and Contingencies

     We lease our facilities under non-cancelable operating leases that require us to pay maintenance and operating expenses, such as taxes, insurance and utilities. We are required pursuant to the terms of facility leases to maintain two standby letters of credit totaling $2.6 million. No amounts have been drawn against these standby letters of credit.

11


Table of Contents

     Rent expense was approximately $0.7 million and $0.6 million for the fiscal quarters ended September 30, 2004 and 2003, respectively and approximately $1.3 million and $1.5 million for the six months ended September 30, 2004 and 2003, respectively. As of September 30, 2004, future minimum lease payments under non-cancelable operating leases (facilities and equipment leases) and sub-lease income due to us under an existing sub-lease of an excess facility are as follows (in thousands):

                                                         
    2005
  2006
  2007
  2008
  2009
  Thereafter
  Total
Contractual Obligations